DelMar Pharmaceuticals Presents Positive Data on the Benefit of VAL-083 in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) - VAL-083 retains activity in chemo-resistant NSCLC tumor types -- VAL-083 demonstrates a super-additive effect in NSCLC when used in combination with platinum-based chemotherapeutic agents -

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 6, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented data on the benefit of VAL-083 (dianhydrogalactitol) in combination with platinum-based chemotherapy regimens in the treatment of non-small cell lung cancer (NSCLC). "We have recently shown that VAL-083's mechanism is distinct from platinum-based chemotherapy, the current standard of care for NSCLC, and is active against platinum and TKI-resistant NSCLC in both in vitro and in vivo models of lung cancer," stated Jeffrey...